Literature DB >> 27746161

Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.

Yuan-Chin Tsai1, Wei-Yu Chen2, Man Kit Siu3, Hong-Yuan Tsai1, Juan Juan Yin4, Jiaoti Huang5, Yen-Nien Liu6.   

Abstract

It has been suggested that ETV6 serves as a tumor suppressor; however, its molecular regulation and cellular functions remain unclear. We used prostate cancer as a model system and demonstrated a molecular mechanism in which ETV6 can be regulated by epidermal growth factor receptor (EGFR) signaling through microRNA-96 (miR-96)-mediated downregulation. In addition, EGFR acts as a transcriptional coactivator that binds to the promoter of primary miR-96 and transcriptionally regulates miR-96 levels. We analyzed two sets of clinical prostate cancer samples, confirmed association patterns that were consistent with the EGFR-miR-96-ETV6 signaling model and demonstrated that the reduced ETV6 levels were associated with malignant prostate cancer. Based on results derived from multiple approaches, we identified the biological functions of ETV6 as a tumor suppressor that inhibits proliferation and metastasis in prostate cancer. We present a molecular mechanism in which EGFR activation leads to the induction of miR-96 expression and suppression of ETV6, which contributes to prostate cancer progression.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone metastasis; ETV6; Epidermal growth factor receptor (EGFR); Prostate cancer; microRNA (miR)-96

Mesh:

Substances:

Year:  2016        PMID: 27746161     DOI: 10.1016/j.canlet.2016.10.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

2.  Oncogenic and tumor-suppressive microRNAs in prostate cancer.

Authors:  Morgan L Zenner; Bethany Baumann; Larisa Nonn
Journal:  Curr Opin Endocr Metab Res       Date:  2020-02-27

Review 3.  MicroRNA-96: A therapeutic and diagnostic tumor marker.

Authors:  Hamid Reza Rahimi; Majid Mojarrad; Meysam Moghbeli
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

4.  Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

Authors:  Ilaha Isali; Mohammed Adel Ali Al-Sadawi; Arshna Qureshi; Ahmad O Khalifa; Mukesh K Agrawal; Sanjeev Shukla
Journal:  Int J Cell Biol Physiol       Date:  2019-10-07

5.  Regulation of cell-cell adhesion in prostate cancer cells by microRNA-96 through upregulation of E-Cadherin and EpCAM.

Authors:  Gjendine Voss; Benedikta S Haflidadóttir; Helena Järemo; Margareta Persson; Tina Catela Ivkovic; Pernilla Wikström; Yvonne Ceder
Journal:  Carcinogenesis       Date:  2020-07-14       Impact factor: 4.944

6.  Comparison of diagnostic value of multi-slice spiral CT and MRI for different pathological stages of prostate cancer.

Authors:  Yanbin Sui; Jian Li; Zhenxing Zou; Yunxia Shi; Cuijuan Hao
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

7.  Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.

Authors:  Hatice U Osmanbeyoglu; Fumiko Shimizu; Angela Rynne-Vidal; Direna Alonso-Curbelo; Hsuan-An Chen; Hannah Y Wen; Tsz-Lun Yeung; Petar Jelinic; Pedram Razavi; Scott W Lowe; Samuel C Mok; Gabriela Chiosis; Douglas A Levine; Christina S Leslie
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 17.694

8.  The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis.

Authors:  Wei Wang; Xia-Bo Shen; Wei Jia; Da-Bing Huang; Yong Wang; Yue-Yin Pan
Journal:  Ther Adv Med Oncol       Date:  2019-05-23       Impact factor: 8.168

Review 9.  ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.

Authors:  AbdulFattah Salah Fararjeh; Yen-Nien Liu
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

10.  Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.

Authors:  Yuan-Chin Tsai; Tao Zeng; Wassim Abou-Kheir; Hsiu-Lien Yeh; Juan Juan Yin; Yi-Chao Lee; Wei-Yu Chen; Yen-Nien Liu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.